Bio-Manufacturing: Mastering Cells with Tunable Precision
Virtual Cell for Cellular Control.
Current Product
Our flagship product, Chemplify™, is a small molecule that enhances T cell therapy by boosting T cell expansion 5-10 times and promoting a younger, healthier state via a novel pathway. This innovation addresses key challenges in T-cell therapeutic manufacturing and presents a unique opportunity to explore an uncharted mechanism that could reshape our understanding of T cell biology.
SaaS model &Future Pipelines
-
We license CelMo in a SaaS model, providing you with secure, on-demand access to our AI-driven platform. CelMo virtualizes biomanufacturing cell systems to rapidly generate and optimize small molecules—reducing costs while enhancing yield and quality.
-
Our AI-designed cellular drugs enhance CHO cell productivity by precisely modulating cellular pathways to increase recombinant protein yield and stability.
-
Our AI creates cellular drugs that help host cells produce more AAVs, making gene therapy manufacturing quicker and more efficient.
Scalable and Cutting-edge AI Platform
Our advanced AI platform enables rapid identification of targets, and de novo development and optimisation of small molecules with targeted biological effects.
Using this platform, we create models to discover targets whose modulation enhances cell activities, and the ideal structure of the molecule that unlocks the cells’ potential in the biologics manufacturing.
Our AI platform has active pipelines in various cell types across different modalities, including small molecules, antibodies, mRNA, etc. We partner with world-leading institutions on the R&D, and serve biotechs, pharma, CDMOs and hospitals with world-class assets.
